Our most promising candidate, amiodarone, reduced bladder cancer growth in vitro and in vivo, an effect that might be mediated by the inhibition of mTOR, with possible implications also for the ERK1/2 pathway. This evidence concerns the gene MAPK3 and urinary bladder carcinoma.